These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

31 related articles for article (PubMed ID: 10697570)

  • 1. Assessment of the extent of unpublished studies in prognostic factor research: a systematic review of p53 immunohistochemistry in bladder cancer as an example.
    Sekula P; Pressler JB; Sauerbrei W; Goebell PJ; Schmitz-Dräger BJ
    BMJ Open; 2016 Aug; 6(8):e009972. PubMed ID: 27531721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discordant Molecular Imaging Findings with 2-[
    Mahalik A; Jaleel J; Sagar S; Khan D; Raju S; Kumar R
    Nucl Med Mol Imaging; 2024 May; 58(3):150-151. PubMed ID: 38633286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of previous cancer on overall survival of bladder cancer patients and the establishment of nomogram for overall survival prediction.
    Wang Z; Zhou Y; Guan C; Ding Y; Tao S; Huang X; Chen L; Zhang F; Zhang R
    Medicine (Baltimore); 2020 Sep; 99(38):e22191. PubMed ID: 32957347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of pre-existing cancer on survival of prostate cancer patients: A population-based study.
    Zhou Y; Guan H; Fu Y; Mao L; Ge J; Liu L; Cheng L; Guan C
    Medicine (Baltimore); 2018 Dec; 97(50):e13479. PubMed ID: 30558003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncologic aspects of long-term followed incidental prostate cancer detected by cystoprostatectomy in Korean patients.
    Cho IC; Kim JE; Kim SH; Joung JY; Seo HK; Chung J; Park WS; Lee KH
    Prostate Int; 2015 Jun; 3(2):56-61. PubMed ID: 26157769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RGD-modifided oncolytic adenovirus exhibited potent cytotoxic effect on CAR-negative bladder cancer-initiating cells.
    Yang Y; Xu H; Shen J; Yang Y; Wu S; Xiao J; Xu Y; Liu XY; Chu L
    Cell Death Dis; 2015 May; 6(5):e1760. PubMed ID: 25973680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synchronous primary malignancies of the male urogenital tract.
    Qarro A; Ammani A; Bazine K; Najoui M; Samir J; Alami M
    Can Urol Assoc J; 2014 May; 8(5-6):E353-5. PubMed ID: 24940463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of synchronous double malignancy: Invasive bladder cancer and Leiomyosarcoma of extremity and review of literature.
    Viveka BK; Amirtham U; Kumar VM; Babu GK
    South Asian J Cancer; 2013 Jul; 2(3):152. PubMed ID: 24455603
    [No Abstract]   [Full Text] [Related]  

  • 9. The incidence and relevance of prostate cancer in radical cystoprostatectomy specimens.
    Alsinnawi M; Loftus B; Flynn R; McDermott T; Grainger R; Thornhill JA
    Int Urol Nephrol; 2012 Dec; 44(6):1705-10. PubMed ID: 22773166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic features of incidental prostatic adenocarcinoma in radical cystoprostatectomy specimens.
    Aytac B; Vuruskan H
    World J Surg Oncol; 2011 Jul; 9():81. PubMed ID: 21774802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of NF-E2-related factor 2 signaling for cancer chemoprevention: antioxidant coupled with antiinflammatory.
    Hu R; Saw CL; Yu R; Kong AN
    Antioxid Redox Signal; 2010 Dec; 13(11):1679-98. PubMed ID: 20486765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors.
    Cordon-Cardo C; Zhang ZF; Dalbagni G; Drobnjak M; Charytonowicz E; Hu SX; Xu HJ; Reuter VE; Benedict WF
    Cancer Res; 1997 Apr; 57(7):1217-21. PubMed ID: 9102201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
    Tzai TS; Tsai YS; Chow NH
    Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The tumor suppressors pRB and p53 as regulators of adipocyte differentiation and function.
    Hallenborg P; Feddersen S; Madsen L; Kristiansen K
    Expert Opin Ther Targets; 2009 Feb; 13(2):235-46. PubMed ID: 19236241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor mechanisms when pRb and p53 are genetically inactivated.
    Zhu L; Lu Z; Zhao H
    Oncogene; 2015 Aug; 34(35):4547-57. PubMed ID: 25486431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of p53 and pRb in bladder and prostate cancers of patients having both cancers.
    Singh A; Jones RF; Friedman H; Hathir S; Soos G; Zabo A; Haas GP
    Anticancer Res; 1999; 19(6B):5415-7. PubMed ID: 10697570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.
    Shariat SF; Tokunaga H; Zhou J; Kim J; Ayala GE; Benedict WF; Lerner SP
    J Clin Oncol; 2004 Mar; 22(6):1014-24. PubMed ID: 14981102
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.